[18F]FDG-PET/CT评估非小细胞肺癌患者免疫治疗非典型反应模式:长期预后评估与临床管理建议
研究前瞻性纳入109例接受免疫检查点抑制剂治疗的非小细胞肺癌患者,在基线、治疗7周后(PETinterim1)和3个月后(PETinterim2)行[18F]FDG-PET/CT。PETinterim1按标准PERCIST评估,进展者继续免疫治疗6周后在PETinterim2识别假性进展、分离反应和确认性进展。中位随访21个月,假性进展/分离反应患者总生存和无进展生存显著优于确认性进展但劣于持续代谢反应,该三分组预后分层优于标准PERCIST。
要点
- PETinterim1时60%(66/109)患者出现PERCIST进展,其中59/66继续免疫治疗。
- PETinterim2时14%为假性进展、11%为分离反应、35%为确认性进展、28%为持续代谢反应。
- 假性进展/分离反应患者总生存和无进展生存显著优于确认性进展(29 vs 9个月,p<0.02;16 vs 2个月,p<0.001)。
核心结论
- [18F]FDG-PET/CT可实现免疫治疗反应的早期评估,所提出的包含免疫相关非典型反应模式的新wsPERCIST(「wait and see」)PET标准可细化基于PERCIST标准的传统预后分层。
研究设计与样本
- 前瞻性纳入109例接受免疫检查点抑制剂治疗的非小细胞肺癌患者,在基线、治疗7周后(PETinterim1)和3个月后(PETinterim2)行[18F]FDG-PET/CT。
- PETinterim1按标准PERCIST评估,出现PERCIST进展者按研究设计继续免疫治疗6周,随后在PETinterim2评估假性进展、分离反应和确认性进展。
- 患者随访至少12个月,中位随访21个月。
主要发现
- PETinterim1时60%(66/109)患者观察到PERCIST进展,其中59/66继续免疫检查点抑制剂治疗。
- PETinterim2时14%患者为假性进展、11%为分离反应、35%为确认性进展、28%为持续代谢反应。
- 假性进展与分离反应的中位总生存(27 vs 29个月,p=1.0)和中位无进展生存(17 vs 12个月,p=0.2)无显著差异。
- 假性进展/分离反应患者的总生存和无进展生存显著优于确认性进展患者(29 vs 9个月,p<0.02;16 vs 2个月,p<0.001),但劣于持续代谢反应患者(p<0.001)。
- 该三分组预后分层能更好地识别真正进展者,其预后价值优于标准PERCIST标准(p=0.03)。
关键数值与推荐
- PERCIST进展定义为PETinterim1时按标准PERCIST标准评估为进展。
- 假性进展定义为PETinterim2时后续代谢反应;分离反应定义为应答与未应答病灶共存;确认性进展定义为后续病灶均匀进展。
- 新wsPERCIST(「wait and see」)PET标准包含免疫相关非典型反应模式,可细化基于PERCIST标准的传统预后分层。
临床怎么用
- 作者提出包含免疫相关非典型反应模式的新wsPERCIST(「wait and see」)PET标准,可细化基于PERCIST标准的传统预后分层。
- 研究设计为PETinterim1出现PERCIST进展者继续免疫治疗6周后再行PETinterim2评估,以识别假性进展、分离反应和确认性进展。
局限性
- 试验注册为回顾性注册(Retrospectively registered)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To determine the long-term prognosis of immune-related response profiles (pseudoprogression and dissociated response), not covered by conventional PERCIST criteria, in patients with non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs). METHODS: 109 patients were prospectively included and underwent [18F]FDG-PET/CT at baseline, after 7 weeks (PETinterim1), and 3 months (PETinterim2) of treatment. On PETinterim1, tumor response was assessed using standard PERCIST criteria. In the event of PERCIST progression at this time-point, the study design provided for continued immunotherapy for 6 more weeks. Additional response patterns were then considered on PETinterim2: pseudo-progression (PsPD, subsequent metabolic response); dissociated response (DR, coexistence of responding and non-responding lesions), and confirmed progressive metabolic disease (cPMD, subsequent homogeneous progression of lesions). Patients were followed up for at least 12 months. RESULTS: Median follow-up was 21 months. At PETinterim1, PERCIST progression was observed in 60% (66/109) of patients and ICPI was continued in 59/66. At the subsequent PETinterim2, 14% of patients showed PsPD, 11% DR, 35% cPMD, and 28% had a sustained metabolic response. Median overall survival (OS) and progression-free-survival (PFS) did not differ between PsPD and DR (27 vs 29 months, p = 1.0; 17 vs 12 months, p = 0.2, respectively). The OS and PFS of PsPD/DR patients were significantly better than those with cPMD (29 vs 9 months, p < 0.02; 16 vs 2 months, p < 0.001), but worse than those with sustained metabolic response (p < 0.001). This 3-group prognostic stratification enabled better identification of true progressors, outperforming the prognostic value of standard PERCIST criteria (p = 0.03). CONCLUSION: [18F]FDG-PET/CT enables early assessment of response to immunotherapy. The new wsPERCIST ("wait and see") PET criteria proposed, comprising immune-related atypical response patterns, can refine conventional prognostic stratification based on PERCIST criteria. TRIAL REGISTRATION: HDH F20230309081206. Registered 20 April 2023. Retrospectively registered.
引用
- Masse M, Chardin D, Tricarico P, et al. [18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal. Eur J Nucl Med Mol Imaging. 2024. PMID: 38896129. doi:10.1007/s00259-024-06794-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。